Global Hand, Foot, and Mouth Disease Market, By Virus Type; By Drug Type; By Route of Administration; By Distribution Channel -Estimation & Forecast, 2017-2030

Global Hand, Foot, and Mouth Disease (HFMD) Market Analysis: Size, Share, Growth, Trends, and Forecast 2017-2030

The Hand, Foot, and Mouth Disease (HFMD) market size was valued at US$ 3.03 Bn in 2022 and is projected to reach US$ 4.67 Bn by 2030, growing at a CAGR of 6.34% during the forecast period. HFMD is a common viral illness affecting children and is marked by fever, sores in the mouth, and a rash on the hands and feet.

Growth Influencers:

Key factors driving the market include rising healthcare expenditure and an increased prevalence of viral infections in children. Additionally, progress in drug development and vaccines for HFMD disease is fuelling the growth of the market. On the other hand, the availability of home remedies acts as a restraint for the market.

Segments Overview:

The market is segmented based on virus type, drug type, route of administration, and distribution channel.

By Virus Type

• Coxsackievirus A16
• Coxsackievirus A6
• Enterovirus 71 (EV-A71)

By Drug Type

• Pain Relievers
• Non-steroidal Anti-inflammatory Drugs
• Nucleoside Analogue Antivirals

By Route of Administration

• Topical
• Oral
• Intravenous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies A16
• Online Pharmacies

The categorization of virus types is led by Coxsackievirus A16, which was the major contributor with a substantial market portion of 54.3% in 2022 and also showcased the highest compound annual growth rate (CAGR) of 6.6%. When it comes to drug types, non-steroidal anti-inflammatory drugs took the lead, capturing 60% of the market in 2022. Considering the routes of administration, the topical category was prominent, securing more than 55% of the market share in 2022. Among different distribution channels, retail pharmacies outperformed others, acquiring the largest market proportion of 47.9% in 2022.

Regional Overview:

The HFMD market is categorized by region into North America, Europe, Asia Pacific, Middle East & Africa, and South America.

North America

• The U.S.
• Canada
• Mexico

Europe

• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe

Asia Pacific

• China
• India
• Japan
• Australia & New Zealand
• South Korea
• ASEAN
• Rest of Asia Pacific

Middle East & Africa (MEA)

• Saudi Arabia
• South Africa
• UAE
• Rest of MEA

South America

• Argentina
• Brazil
• Rest of South America

Asia Pacific leads with a market share of 54.0% in 2022 and the fastest CAGR of 6.7%. North America's market is expected to reach US$ 1046.6 Mn by 2030.

Competitive Landscape:

Major players include Emergex Vaccines Ltd, Bejing Vigoo Biological Co., Ltd., Shanghai Zerun Biotechnology, Sentinext Therapeutics, Sinovac Biotech, among others. These companies are focusing on strategies such as the development of new vaccines, expansion into international markets, and acquisition of new production lines, technologies, businesses, products, or services.

Report Insight:

The report provides additional insights such as:

• Epidemiology of Hand, Foot, and Mouth Disease
• Recent progress and challenges in drug development for HFMD
• Mechanism of action for HFMD virus inhibitors
• HFMD Vaccines in the pipeline
• Vaccine Development Pipeline - by Company
• Cost of medical services and over-the-counter medications without insurance for HFMD
• Key Manufacturers - Based on Drug Types

Questions to be answered:

• What are the key trends and growth prospects for the HFMD market until 2030?
• How will the advancements in drug and vaccine development influence the market growth?
• Which region will exhibit the highest growth rate in the coming years?
• How will the changing healthcare expenditure affect the global HFMD market?
• What strategies are key market players adopting to ensure sustained growth?